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ABSTRACT: Kendomycin is a small-molecule natural product that
has gained significant attention due to reported cytotoxicity against
pathogenic bacteria and fungi as well as a number of cancer cell lines.
Despite significant biomedical interest and attempts to reveal its
mechanism of action, the cellular target of kendomycin remains
disputed. Herein it is shown that kendomycin induces cellular
responses indicative of cation stress comparable to the effects of
established iron chelators. Furthermore, addition of excess iron and
copper attenuated kendomycin cytotoxicity in bacteria, yeast, and
mammalian cells. Finally, NMR analysis demonstrated a direct interaction with cations, corroborating a close link between the
observed kendomycin polypharmacology across different species and modulation of iron and/or copper levels.
Natural products serve as privileged chemical probes forinterrogating cellular biology, expanding the druggable
genome, and eventually developing new therapeutics. The
secondary metabolite kendomycin (Figure 1A) is a macrocyclic
polyketide produced by several Streptomyces species. Since its
discovery, a variety of cytotoxic activities, including killing of
both Gram-negative and -positive bacteria,1 pathogenic fungi,2
and a number of human cancer cell lines,2 were reported. This
generated substantial interest in kendomycin, leading to the
establishment of a total synthesis method3 and identification
and cloning of its corresponding polyketide synthase cluster.4
Kendomycin was proposed to inhibit yeast and mammalian
proteasomes,5 but whereas a specific covalent interaction was
reported, binding site mutations that abolished the interaction
failed to alter kendomycin cytotoxicity.5 Conservation of
cytotoxic activity from bacteria to man may be indicative of
either a highly conserved protein target or interference with
common biomolecules such as nucleic acids, lipids, or ions. It
was the aim of this study to identify the mechanism of action
of kendomycin and thereby explain its pan-species activity.
■ RESULTS AND DISCUSSION
Kendomycin was previously characterized as a weak inhibitor
of yeast and mammalian proteasomes.5 To test whether
proteasome inhibition plays a role in kendomycin cytotoxicity
in human cells, a FACS-based proteasomal degradation assay
was used that monitors cellular turnover of a destabilized
UbG76V-GFP reporter as a measure of proteasome activity.6
As expected, treating cells with the established proteasome
inhibitor MG132 resulted in cellular accumulation of GFP.
However, kendomycin failed to increase cellular GFP
fluorescence even at acutely cytotoxic concentrations (Figures
1B and S1, Supporting Information), suggesting direct
proteasome inhibition is not likely the primary mechanism of
action of kendomycin.2
Kendomycin has been shown to affect the uptake of
radiolabeled isoleucine in bacteria, indicative of protein
synthesis inhibition.7 To investigate the proposed kendomycin
mechanism of action in mammalian cells, metabolic labeling of
HCT116 cells with 35S methionine/cysteine was used. As
expected, treatment with an established ribosomal inhibitor
cycloheximide abolished all protein synthesis, while the Sec61
translocation inhibitor apratoxin A8 prevented biogenesis only
of newly labeled secretory proteins. In contrast to cyclo-
heximide or apratoxin A, kendomycin did not influence
production of total or secretory proteins (Figure 1C).
Therefore, inhibition of protein biogenesis is also not a likely
primary mechanism by which kendomycin exerts its cytotoxic
effect across a range of species.
Mutations at the target binding site of cytotoxic compounds
can interfere with compound binding without affecting target
functionality, and isolation and characterization of such
resistance-conferring point mutations is the method of choice
for identifying targets of cytotoxic compounds.9−11 Given the
broad cytotoxic range of kendomycin, both yeast and
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mammalian cells were randomly mutagenized by ethyl
methanesulfonate and screened for permissive kendomycin-
resistant mutants. In total, 48 Saccharomyces cerevisiae colonies
were isolated, grown to saturation in the absence of drug, and
then replated on agar supplemented with kendomycin.
However, no resistance was observed to persist in any clones
using this approach, indicating that initial resistance was
obtained through adaptation rather than mutation. Analo-
Figure 1. Kendomycin toxicity is not concurrent with proteostatic perturbations. (A) Structure of kendomycin. (B) Kendomycin treatment does
not inhibit proteasome activity in mammalian cells. Fluorescence distribution of DMSO (gray infill), 250 nM MG132 (black), and 250 nM
kendomycin (green) treated HEK293T cells expressing UbG76V-GFP proteosomal reporter and quantification from S1, Supporting Information.
(C) HCT-116 cells grown in the presence of indicated concentrations of kendomycin, apratoxin A (inhibitor of the Sec61 protein translocon), or
cycloheximide (protein synthesis inhibitor) and 35S-labeled methionine/cysteine. Total protein shows cellular lysate; secreted protein shows the
contents of the growth medium following TCA precipitation. As expected, cycloheximide inhibits protein biogenesis in both total and secreted
fractions, while apratoxin A inhibits biogenesis of only secreted proteins. Kendomycin has no effect on biogenesis of either total or secreted
fractions.
Figure 2. Chemogenomic profiling identifies a conserved link between iron dependence and kendomycin sensitivity. (A) The IC50 values of
kendomycin are plotted against those of mycobactin A, resulting in a Pearson correlation coefficient (R) of 0.71, suggesting that kendomycin might
utilize a similar mechanism of action to the bacterial siderophore. (B) HIP profile of kendomycin tested in two independent biological replicates at
16.5 μM. Sensitivity of the heterozygous deletion strains is plotted against statistical significance (z-score) as previously described.1 Black dots
represent nonessential and gray squares essential genes of the S. cerevisiae genome. Alignment of the z-scores of kendomycin and the clinical cation
chelator exjade reveals a conserved set of hypersensitive hits, shown in (C), providing further evidence that kendomycin shares a similar mechanism
of action with cation chelators in general. The relative gene-level depletion (D) and the enrichment (E) scores from an inhibitor-sensitized CRISPR
screen of kendomycin at 400 nM in HCT116 cells are shown. The RSA p-value, a gene-level measure for conserved depletion (RSA down) or
enrichment (RSA up) of its respective guides, is plotted against Q, a gene-level effect size corresponding to the RSA p-value for depletion (Q1) or
enrichment (Q3). The most significant hits reveal an abundance of iron interactive processes.
Journal of Natural Products pubs.acs.org/jnp Article
https://dx.doi.org/10.1021/acs.jnatprod.9b00826
J. Nat. Prod. 2020, 83, 965−971
966
gously, 18 resistant clonal HCT116 cell lines were identified
that were subjected to whole-genome sequencing. The
resulting SNP data identified many mutations, but none of
these were enriched at particular genes or cellular pathways
(Table S1, Supporting Information). Together, these results
are in accordance with an earlier global proteomic response
study,2 which identified numerous kendomycin-modulated
proteins spreading throughout multiple diverse biological
processes, but lacking an obvious functional connection.
Together, these results suggest that the target of kendomycin
may not be a valid target of mutagenesis.
To identify the mechanism of action of kendomycin by an
alternative unbiased approach, it was assayed against the
Cancer Cell Line Encyclopedia, a collection of 512 human
cancer cell lines (broadinstitute.org/ccle) with established
sensitivities to a host of drug-like small molecules.12 When
querying the distribution of antiproliferative IC50 values against
the tested compounds, the closest correlation with kendomycin
(R = 0.71) was observed with the iron-chelating siderophore
mycobactin A12 (Figure 2A), despite a lack of structural
similarity between the two compounds. This prompted the
hypothesis that kendomycin may exert its cytotoxic effect by
cation modulation. Thus, it was attempted to assess
kendomycin impact on yeast cells in an unbiased, genome-
wide manner by chemogenomic haploinsufficiency profiling
(HIP), a gene dosage-dependent method that assesses the
effect of compounds against S. cerevisiae targets and pathways13
and can also reveal compound mechanisms not directly
targeting a protein.14,15 Consistent with the hypothesis that
kendomycin might act through a nonprotein target, the HIP
profile of kendomycin did not reveal strongly affected
heterozygous deletion strains (Figure 2B). The most
pronounced effect was observed in a heterozygous deletion
of AFT2, an iron-regulated transcriptional activator that
activates genes involved in iron homeostasis.16 Weaker, but
still statistically significant hits included a heterozygous
deletion of an uncharacterized ORF YIL102C, reported to be
sensitive to Al(III),17 and the galactose permease GAL2. When
correlating this profile to our database of >3000 HIP profiles,
an overlap of hits with the clinical cation chelator Exjade was
apparent (Figure 2C), providing further experimental support
for cation modulation by kendomycin.
A similar chemogenomic profiling experiment was per-
formed in human cells using CRISPR/Cas9-mediated gene
attenuation, as previously published.18 The obtained sequenc-
ing data were plotted to identify genes for which the
modulation can confer hypersensitivity (Figure 2D) or
hyper-resistance (Figure 2E). Genes that conferred hyper-
sensitivity against kendomycin were the mitochondrial E3
ubiquitin ligase MARCH5, involved in stress-induced
apoptosis,19 and the mitochondrial membrane protein OPA3,
reported to exert cell-protective functions.20 Weaker, but
Figure 3. Exogenous cations ameliorate kendomycin cytotoxicity across species. Spectra of 250 μM kendomycin with increasing concentrations of
iron (A) or copper (B). A320 were measured in quadruplicate, and average values used to estimate a binding curve for each (A and B, bottom), from
which Kapp was determined. (C) Kinetics of kendomycin toxicity and rescue by supplementation with 0.5 mM FeCl2 in HCT116 cells. Cell
proliferation in the presence of kendomycin is halted at 10 h, while Fe(II) supplementation allows continued proliferation. Dose−response curves
of kendomycin were performed in the presence and absence of (D) 0.25 mM FeCl2 and 0.25 mM CuCl2 against B. subtilis, (E) 1 mM FeCl2 and
0.25 mM CuCl2 against S. cerevisiae on solid medium, and (F) 0.5 mM FeCl2 and 0.5 mM CuCl2 against HCT116 cells in duplicate, and inhibition
curves were fitted by regression. Shift in the dose−response curves indicates that cation supplementation ameliorates kendomycin toxicity under
these conditions.
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statistically significant hits included the iron responsive
element binding protein 2, IREB2, the ABC transporter
ABCC1, which transports dinitrosyl-dithiol-iron complexes,21
GCLC, the rate-limiting enzyme of glutathione synthesis
essential for iron−sulfur cluster formation,22 and XIAP, the
iron- and copper-dependent X-linked inhibitor of apopto-
sis.23,24 Most of the mammalian hypersensitive hits were
directly linked to iron metabolism or were closely connected to
iron-dependent processes. The hits conferring hyper-resistance
exclusively comprised genes directly linked to mitochondrial
protein synthesis such as subunits of the mito-ribosome and
different tRNA synthetases. Mitochondria, the major consum-
ers of cellular iron, are dispensable in the high-glucose medium
routinely used in mammalian tissue culture, reducing cellular
iron demand.20 This may explain the frequency of iron
metabolism-regulating genes in the resistance profile. Taken
together, the data obtained from yeast and mammalian cells
support interference of kendomycin with iron-dependent
processes.
Next, it was desired to test whether addition of exogenous
iron or other cations could modulate kendomycin activity.
Mixing kendomycin with iron or copper in a test tube resulted
in a concentration-dependent color change suggestive of a
direct interaction (Figure S2, Supporting Information).
Importantly, no color change was observed with other cations,
including calcium, cobalt, magnesium, or manganese, indicative
of highly selective cation chelation. To quantitatively
determine relative affinities for kendomycin toward different
physiologically relevant cations, an absorbance-based assay was
used. The characteristic A320 nm absorbance peak of
kendomycin was effectively quenched by addition of selected
cations Fe(II), Fe(III), or Cu(II) (Figure 3A and B, Figure S2,
Supporting Information). Conversely, addition of Ca2+ or Mg2+
did not cause any detectable changes in the UV spectra,
suggesting a lack of interaction with these cations (Figure S2,
Supporting Information). Modeling the concentration-depend-
ent quenching allowed determination of kendomycin affinities
toward different cations. Based on this analysis, the apparent
kendomycin affinities were Kapp 19 μM (Fe(II)), 48 μM
(Cu(II)), and 76 μM (Fe(III)), with no observed binding for
calcium or magnesium. Further, supplementing cultures of B.
subtilis (Figure 3D), S. cerevisiae (Figure 3E), or human
HCT116 colon carcinoma cells (Figures 3C and F) with iron
partially alleviated cytotoxicity in all three species, consistent
with the essential role of iron for viability of all forms of life.25
In contrast, copper rescued kendomycin cytotoxicity only in
bacteria and yeast under these conditions, possibly reflecting
the mechanisms that these species use to tightly regulate free
copper and mitigate its antimicrobial effect.26
Having established a plausible link between cation
availability and kendomycin cytotoxicity, it was sought to
demonstrate direct cation binding. To test this, the complete
chemical shift assignment of kendomycin using 1D and 2D
NMR approaches was determined (Figure S3, Supporting
Information) followed by measurements in the presence of
different cations. Addition of iron(II) or copper(II) resulted in
a dose-dependent shift and broadening of the NMR signals
(Cu(II) Figure 4A; Fe(II) Figure S4, Supporting Information)
and a decreased overall intensity of kendomycin signals. Based
on the magnitude of the paramagnetic effect of the metal ions,
we were able to derive a rough epitope mapping27 indicating
the 2,5-dihydroxy-7-methyl-1-benzofuran-6(2H)-one moiety as
the metal ion binding site (Figure 4C). In order to prove the
presence of a coordination complex and to rule out redox-
based mechanisms, the kendomycin−copper complex was
quenched with TFA, reverting the 1H NMR spectrum to one
Figure 4. Kendomycin cation binding. (A) 1H NMR spectra of 4 mM kendomycin with increasing concentrations of CuSO4: 0 (black), 0.33 (red),
0.66 (blue), and 1 equivalent (green). See Figure S3 in the Supporting Information for complete chemical shift assignments. (B) 1H NMR spectra
of kendomycin (black) and of kendomycin treated with 1 equivalent of aqueous CuSO4 and quenched after 1 day with TFA (red) prior to analysis.
Protected peak is indicative of the copper interaction site. (C) Proposed kendomycin Cu(II) complex and potential mechanism for H/D exchange
(axial water not shown for better representation).
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identical to the parent compound with only H-24 missing
(Figure 4B).
LC-MS experiments of the TFA-quenched complex
indicated that the lack of this signal can be attributed to H/
D exchange (Figure S4, Supporting Information). Using time-
dependent quenching experiments, we could show that the H/
D exchange occurs with an approximate rate constant of k ≈
0.06 h−1 (Figure S5, Supporting Information). Since no H/D
exchange was observed in the absence of copper or iron ions, it
was postulated that the underlying mechanism is linked to the
metal binding mode in the complex. Assuming a geometry
similar to other hydroxyquinone copper(II) complexes,28 a 2:1
stoichiometry with a bidentate kendomycin ligand can be
proposed. This binding mode could explain the observed H/D
exchange via an opening of the hemiketal in equilibrium
(Figure 4C). Other molecular mechanisms such as proton-
coupled electron transfer for the quinone ligand might be
included but were not resolved with the experimental setup
used in this study.
In summary, genome-wide and focused data sets generated
in yeast and mammalian cells, as well as molecular data, all
indicate that the reported activities of kendomycin are attained
by sequestration of iron and copper. Since iron is vital for all
phyla, this also explains the pan-species activity of kendomycin.
Oxidative stress and cation imbalance are linked to many
diseases, and chelating natural products such as curcumin and
gossypol29−31 or salinomycin,32 which sequesters lysosomal
iron, have accepted clinical benefits. This report thus provides
a direction for further, focused investigations of clinical
applications of kendomycin.
■ EXPERIMENTAL SECTION
General Experimental Procedures. Kendomycin was isolated
from an unclassified Actinomycetes strain grown in a submerged
culture. A crude extract was generated by extraction of the culture
broth with ethyl acetate, and kendomycin was purified by subsequent
normal-phase and reversed-phase chromatographic separations. The
final purity was assessed by HPLC coupled to UV−vis, MS, and
charged aerosol detectors and found to be at least 97%.
Effects of the Proteasome Inhibitor MG132 and Kendomy-
cin on Cellular Turnover of a Destabilized UbG76V-GFP
Reporter. K562 cells bearing the lentivirally integrated ubiquitin
fusion degradation reporter UbG76V-GFP6 controlled by an inducible
TRE2 promoter were induced 16 h prior to addition of compounds
by adding doxycycline to a final concentration of 1 μg/mL. Induced
cells were treated with the indicated compounds or carrier for 4 h,
then analyzed by flow-cytometry on a BD LSRFortessa instrument
(BD Biosciences).
Metabolic Labeling. HCT116 cells were seeded onto six-well
plates (0.5 × 106 cells/well) and then incubated at 37 °C at 5% CO2
for 24 h. Cells were washed twice, and 1 mL of compound diluted in
DMEM lacking methionine and cysteine was added to each well. The
plate was then incubated at 37 °C for 30 min prior to addition of 100
μCi 35S-labeled methionine/cysteine (Expre35s35s protein labeling
mix). Plates were incubated for a further 90 min; then medium was
collected and cells were harvested by scraping after four washes in ice-
cold PBS. Total protein was acquired by RIPA extraction from the cell
pellet, and secreted proteins were acquired by TCA precipitation of
the medium. Gel-exposed storage phosphor screens were scanned on
a Typhoon 9400 variable-mode imager.
EMS Mutagenesis. Strain BY4743Δ8, derived from BY4741 but
deleted for eight genes involved in drug resistance (efflux pumps:
SNQ2, PDR5, YOR1; transcription factors: PDR1, PDR2, PDR3,
YAP1, YRM1), was incubated in 2.5% ethyl methanesulfonate until
only 50% of the cells formed colonies. A total of 2 × 107 mutagenized
cells were plated on two 14 cm dishes containing growth inhibitory
concentrations of kendomycin. After 4 days, resistant colonies could
be isolated and were restreaked onto selective plates. Detailed
experimental procedures were followed as described.33
Chemogenetic Screening. HCT116 cells were grown in
McCoy’s 5A medium supplemented with 10% fetal bovine serum
(FBS). EMS-mutagenized and untreated cells were seeded in 10 cm
dishes at a density of 0.5 × 106 cells/dish. Then, 24 h after plating the
medium was removed and replaced with media containing a range of
concentrations of the compound. Selection was maintained for 14
days by replacement of medium and compound every 48−72 h.
Colonies were isolated from selection plates at an uppermost selection
concentration of 2 μM kendomycin. Resistance of isolated cell lines to
a panel of cytotoxic compounds compared to the parental pool of
HCT116 cells and cell lines showing generalized increase in resistance
were discarded. In total 18 cell lines showing mild resistance to
kendomycin were obtained, eight of which were derived from cells
that were treated with EMS 24 h prior to initiation of selection as
described.34 Confirmed cell lines were then subjected to whole-
genome sequencing.
Chemogenomic Profiling. Yeast haploinsufficiency profiling,14
measuring individual kendomycin hypersensitivity of a genome-wide
collection of heterozygous deletion strains relative to the isogenic
wild-type; CRISPR profiling, measuring hypersensitivity of HCT116
mammalian cells transduced with a genome-wide sgRNA library
resulting in editing of all annotated protein-coding genes;18 and
CCLE profiling,10 measuring IC50 curves of cytotoxic compounds
against the Cancer Cell Line Encyclopedia, were performed as
described.
Bacterial Growth Inhibition. Mid logarithmic B. subtilis cultures
in LB medium samples were back-diluted to low optical density, and
125 μL of cultures was dispensed with an electronic multichannel
pipet into a 96-well plate. Then, 5 μL from an 8-point kendomycin
serial dilution series was added to the wells of six columns to allow for
data sets in duplicates. Two columns were supplemented with freshly
prepared 0.25 mM FeCl2 or 0.25 mM CuCl2, respectively. Plates were
incubated at 37 °C with 1000 rpm orbital shaking, and cell densities
determined by A600.
Yeast Growth Inhibition. Single-colony inhibition was per-
formed as described.33 Colonies were then washed off the plates with
1 mL of PBS, and cell densities determined by A600 measurement.
Mammalian Growth Inhibition. HCT-116 cells were main-
tained at 37 °C, 5% CO2 in McCoy’s 5A medium supplemented with
10% FBS. For cell proliferation assays, cells were seeded in 96-well
viewplates (PerkinElmer, cat. no. 6005182) at a density of 2500 cells/
well. Then, 16 h after plating the cells were treated with the indicated
compounds or carrier. Next, 72 h after compound dosing the medium
was supplemented with 10% Alamar Blue (resazurin) and the cells
were returned to the incubator for a further 4 h. Fluorescence
intensity (excitation 580 nm, emission 620 nm) was measured using a
microplate reader (PerkinElmer EnSpire). Viability was calculated as a
percentage of maximal growth under carrier, and dose−response
curves were calculated using GraphPad Prism 7. Dose−response
curves were calculated from quadruplicate technical replicates.
For cell imaging time courses, cells were seeded in 24-well imaging
plates (Nunc Nunclon-treated multiwell dishes) at a density of 25 000
cells/well. Then, 16 h after plating, the cells were treated with
indicated compounds or carrier. Immediately following dosing, plates
were loaded into a precalibrated CellIQ continuous cell culturing
platform. Cultures were imaged at 3 points per condition every 10
min for 48 h.
NMR Analysis. Standard 1D and 2D NMR methodology was
applied for structure elucidation and titration experiments. For NMR
spectral assignment, 0.4 mg of kendomycin was dissolved in 500 μL of
DMSO-d6/D2O (80%:20% v/v). The obtained clear solution was
transferred into a 5.0 mm NMR sample tube for measurement. 1H
and 13C detected 1D and 2D NMR spectra of the sample were
recorded at 300 K using a Bruker 600 MHz AVANCE III HD
spectrometer equipped with a 5.0 mm 13C{1H} CryoProbe with a z-
gradient system. For titration experiments 1.0 mg of kendomycin was
dissolved in 600 μL of DMSO-d6/D2O (85%:15% v/v) in the
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presence of 0.33, 0.66, and 1.0 equiv of either CuSO4 or FeSO4. The
obtained orange to dark red solutions were transferred into 5.0 mm
NMR sample tubes prior to acquisition. 1H NMR data were recorded
at 300 K using a Bruker 500 MHz AVANCE III spectrometer
equipped with a 5 mm BBO probe with a z-gradient system. All
spectra were referenced according to the internal solvent signal (1H:
DMSO = 2.50 ppm and 13C: DMSO = 39.5 ppm).
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